This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Machens, A. Articles by Dralle, H. Search for Related Content PubMed PubMed Citation Articles by Machens, A. Articles by Dralle, H.

Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical Properties¹

Departments of General Surgery (A.M., O.G., H.D.) and Pathology (R.H.), Martin Luther University Halle-Wittenberg, D-06097 Halle/Saale; Institute for Hormone and Fertility Research, University of Hamburg, Molecular Diagnostic Group (W.H.), D-22529 Hamburg; and Division of Endocrinology, Department of Internal Medicine I, University of Ulm (B.O.B.), D-89081 Ulm, Germany

Address all correspondence and requests for reprints to: Andreas Machens, M.D., Department of General Surgery, Martin Luther University Halle-Wittenberg, Ernst Grube Strasse 40, D-06097 Halle/Saale, Germany.

In hereditary medullary thyroid carcinoma (MTC), few genotype-phenotype correlations have been established. RET genotypes (exons 10, 11, 13, and 14) of 63 patients with hereditary MTC (from November 1994 to October 1999) were correlated with age at diagnosis, sex, the TNM system, and basal calcitonin levels. Mutations in exons 10, 11, 13, and 14 were demonstrated in 22% (14 of 63), 54% (34 of 63), 21% (13 of 63), and 3% (2 of 63). The median ages at diagnosis differed significantly (38, 27, 52, and 62 yr; P = 0.003). When grouped by cysteine codons (exons 10 and 11 vs. exons 13 and 14), this difference became even more evident (30 vs. 56 yr; P = 0.001). Apart from age at diagnosis, no other significant associations were noted. Based hereon, three MTC risk groups were devised according to genotype: a high risk group (codons 634 and 618) with the youngest ages of 3 and 7 yr at diagnosis; an intermediate risk group (codons 790, 620, and 611) with ages of 12, 34, and 42 yr; and a low risk group (codons 768 and 804) with ages of 47 and 60 yr, respectively. Age at diagnosis was unrelated to specific nucleotide and amino acid exchange within each codon.

The current data demonstrate that there is a significant genotype-phenotype correlation, allowing for a more individualized approach to the timing and extent of prophylactic surgery.

This article has been cited by other articles:

				W. van Veelen, C. J.R. van Gasteren, D. S. Acton, D. S. Franklin, R. Berger, C. J.M. Lips, and J. W.M. Hoppener Synergistic Effect of Oncogenic RET and Loss of p18 on Medullary Thyroid Carcinoma Development Cancer Res., March 1, 2008; 68(5): 1329 - 1337. [Abstract] [Full Text] [PDF]

				V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, F. Persson, G. Stenman, C. Sward, B. Wangberg, M. Stridsberg, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr. Relat. Cancer, June 1, 2007; 14(2): 433 - 444. [Abstract] [Full Text] [PDF]

				E. Korpershoek, B.-J. Petri, F. H van Nederveen, W. N M Dinjens, A. A Verhofstad, W. W de Herder, S. Schmid, A. Perren, P. Komminoth, and R. R de Krijger Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma Endocr. Relat. Cancer, June 1, 2007; 14(2): 453 - 462. [Abstract] [Full Text] [PDF]

				K Frank-Raue, H Buhr, H Dralle, E Klar, N Senninger, T Weber, S Rondot, W Hoppner, and F Raue Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur. J. Endocrinol., August 1, 2006; 155(2): 229 - 236. [Abstract] [Full Text] [PDF]

				K. Frank-Raue, S. Rondot, W. Hoeppner, P. Goretzki, F. Raue, and W. Meng Coincidence of Multiple Endocrine Neoplasia Types 1 and 2: Mutations in the RET Protooncogene and MEN1 Tumor Suppressor Gene in a Family Presenting with Recurrent Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4063 - 4067. [Abstract] [Full Text] [PDF]

				S Jindrichova, J Vcelak, P Vlcek, M Neradilova, J Nemec, and B Bendlova Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic J. Endocrinol., November 1, 2004; 183(2): 257 - 265. [Abstract] [Full Text] [PDF]

				E. Arighi, A. Popsueva, D. Degl'Innocenti, M. G. Borrello, C. Carniti, N. M. Perala, M. A. Pierotti, and H. Sariola Biological Effects of the Dual Phenotypic Janus Mutation of ret Cosegregating with Both Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease Mol. Endocrinol., April 1, 2004; 18(4): 1004 - 1017. [Abstract] [Full Text] [PDF]

				A. Machens, P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T. J. van Vroonhoven, H.-D. Roeher, R. A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, et al. Early Malignant Progression of Hereditary Medullary Thyroid Cancer N. Engl. J. Med., October 16, 2003; 349(16): 1517 - 1525. [Abstract] [Full Text] [PDF]

				M. K. Punales, H. Graf, J. L. Gross, and A. L. Maia RET Codon 634 Mutations in Multiple Endocrine Neoplasia Type 2: Variable Clinical Features and Clinical Outcome J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2644 - 2649. [Abstract] [Full Text] [PDF]

				G. Szinnai, C. Meier, P. Komminoth, and U. W. Zumsteg Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis Pediatrics, February 1, 2003; 111(2): e132 - 139. [Abstract] [Full Text] [PDF]

				F. H. Menko, R. B. van der Luijt, I. A. J. de Valk, A. W. F. T. Toorians, J. M. Sepers, P. J. van Diest, and C. J. M. Lips Atypical MEN Type 2B Associated with Two Germline RET Mutations on the Same Allele Not Involving Codon 918 J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 393 - 397. [Abstract] [Full Text] [PDF]